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Abstract
Background: Conjugated linoleic acids (CLA), and principally c9t11 CLA, are suspected to have numerous preventive
properties regarding non-infectious pathologies such as inflammatory diseases, atherosclerosis and several types of cancer.
C9t11 CLA is produced in the rumen during biohydrogenation of linoleic acid, but can also be synthesized in mammalian
tissues from trans-vaccenic acid (C18:1 t11) through the action of delta-9 desaturase (D9D). For several years, it is also known
that c9t11 CLA can be synthesized from conjugated linolenic acids (CLnA), i.e. c9t11c13 CLnA and c9t11t13 CLnA. This study
aimed at investigating to which extent and by which route c9t11 CLA can be produced from another isomer of CLA, the
t11t13 CLA that is structurally very similar to c9t11t13 CLnA, in Caco-2 cells.
Methodology/Principal Findings: Caco-2 cells were incubated for 24 h with 20 mmol/l of t11t13 CLA in the absence or
presence of sterculic oil used as an inhibitor of D9D. Caco-2 cells were able to convert t11t13 CLA into c9t11 CLA, and
c9t11t13 CLnA was formed as an intermediate compound. In the presence of sterculic oil, the production of this
intermediate was decreased by 46% and the formation of c9t11 CLA was decreased by 26%. No other metabolite was
detected.
Conclusions/Significance: These results not only highlight the conversion of t11t13 CLA into c9t11 CLA but demonstrate
also that this conversion involves first a desaturation step catalysed by D9D to produce c9t11t13 CLnA and then the action
of another enzyme reducing the double bond on the D13 position.
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Introduction
For about thirty years, numerous studies have focused on
conjugated linoleic acids (CLA) and their beneficial effects on
animal and human health. CLA is a collective term to describe a
class of geometric and positional isomers of linoleic acid, essentially
present in products derived from ruminants [1,2]. The most
abundant isomer of CLA is the cis-9, trans-11 CLA (c9t11 CLA),
also named rumenic acid, which represents about 80–90% of the
total CLA of dairy products [1–4]. Several studies have
highlighted that c9t11 CLA has interesting properties that may
improve human health. Pariza & Hargraves [5] first reported the
anticarcinogenic properties of partially-purified extracts from
grilled ground beef. Later, many other authors demonstrated that
CLA has beneficial effects regarding the prevention against some
cancers in vivo [6–8] and inhibits cell proliferation of cancer cells in
vitro [9–11]. In addition, CLA has also shown anti-atherosclerotic
[12,13] and anti-inflammatory [3,14,15] properties.
The c9t11 CLA found in the fat of dairy products originates
from two distinct sources. The first origin of c9t11 CLA is its
formation during the ruminal biohydrogenation of linoleic acid
[2–4]. C9t11 CLA can thus be viewed as an intermediate
compound produced during the microbial conversion of linoleic
acid to stearic acid. Some c9t11 CLA escape from ruminal
biohydrogenation, are absorbed at the intestinal level and can be
transferred to the animal tissues and the milk produced. The
second origin of c9t11 CLA is synthesis within the tissue from trans-
vaccenic acid (C18:1 t11, TVA), another important intermediate
compound produced during the biohydrogenation process, which
also partly escapes from the rumen before being absorbed by the
intestine. This endogenous synthesis of c9t11 CLA from TVA is
due to the action of delta-9 desaturase (D9D). It occurs in lactating
cows [16–18] as well as in humans [19], mice [20], cultured MCF-
7 and SW480 cells [21], and represents the primary source of
tissular c9t11 CLA.
Alternative biohydrogenation pathways lead to the production
of a whole range of fatty acid metabolites including additional
CLA isomers. T11t13 CLA is one of the minor isomers found in
dairy fat [22]. Its level can however be increased by a supply of
high linolenic acid oil to dairy cows [23,24]. A recent study
showed that the t11t13 CLA isomer given to human intestinal
HT-29 cells was partially converted to c9t11 CLA [25]. This very
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another one did unfortunately not elucidate the biochemical
pathway involved.
Conjugated fatty acids other than CLA are found in some seed
oils. These are isomers of a–linolenic acid containing three
conjugated double bonds and are named conjugated linolenic
acids (CLnA) [26]. As an example, punicic acid (c9t11c13 CLnA)
is found at up to 83% of total fatty acids in pomegranate (Punica
granatum) seed oil and a–eleostearic acid (c9t11t13 CLnA) at up to
67.7% and 56.2% in tung and bitter gourd (Momordica charantia)
seed oils, respectively [27]. It has been reported in the literature
that these two CLnA, closely similar to the c9t11 CLA in terms of
structure, can be converted into c9t11 CLA in rats, mice and
humans when the corresponding oil was provided to the subjects
[28–32]. In accordance with these in vivo data, we very recently
observed the same conversions in Caco-2 cells used as an in vitro
model of the human intestinal epithelium [33]. The consumption
of CLnA gives thus another way than the dietary intake of dairy
products to produce c9t11 CLA in mammals. It is therefore a third
source of supply of this fatty acid.
In the present study, we aimed to determine the extent and
through which biochemical pathway the isomer t11t13 CLA can
be converted into c9t11 CLA in Caco-2 cells. With the exception
of the cis double bond in D9 position, t11t13 CLA is structurally
similar to c9t11t13 CLnA that can be converted into c9t11 CLA in
Caco-2 cells by the reduction of the double bond in the D13
position [33]. Two alternative pathways can be proposed for the
formation of c9t11 CLA from t11t13 CLA (Figure 1). Either,
t11t13 CLA first undergoes a desaturation step catalysed by the
D9D and is then reduced in its D13 position, or t11t13 CLA is first
reduced in its D13 position and then becomes the substrate of the
D9D. The intermediate compound formed would thus be
c9t11t13 CLnA in the first case and TVA in the second case.
To elucidate if one of these two proposed pathways takes place in
Caco-2 cells, intermediates were measured in cells incubated with
t11t13 CLA for 24 h. In addition, sterculic oil (SO) was used as an
inhibitor of the D9D activity in order to modulate the
accumulation of the intermediate compounds. Indeed, SO
contains about 60% of sterculic acid [8-(2-octyl-1-cyclopropenyl)
octanoic acid] and about 10% of malvalic acid [7-(2-octyl-1-
cyclopropenyl) heptanoic acid], which are known to inhibit the
D9D activity [34,35].
Materials and Methods
Cell culture
Caco-2 cells were purchased from the American Type Culture
Collection (ATCC; Rockville, MD) and were used between
passages 43 to 51. Cells were cultured in a serum-free hormono-
defined synthetic medium (Basal Defined Medium or BDM
[36,37]). This medium was composed of a 5:5:1 (v:v:v) mixture of
Iscove’s Modified Dubelcco’s Medium (IMDM; Lonza, Verviers,
BE), Ham’s F12 medium (Lonza) and NCTC-135 (Invitrogen,
Carlsbad, CA) supplemented with 1% (v:v) non-essential amino
acids (Lonza), 2 mmol/l L-glutamine (Lonza), 0.06 mmol/l
ethanolamine (Sigma-Aldrich, St Louis, MO), 1 ng/ml epidermal
growth factor (Sigma-Aldrich), 100 nmol/l hydrocortisone (Sigma-
Aldrich), 2 nmol/l triiodothyrosin (Sigma-Aldrich), 1 mg/ml
insulin (Sigma-Aldrich), 10 mg/ml albumin complexed to linoleic
acid (Sigma-Aldrich) and 3 g/l NaHCO3 (Sigma-Aldrich). Caco-2
cells were maintained at 37uC in a humidified atmosphere made of
5% CO2 (v:v) in air. Cells were sub-cultured after reaching 90%
confluence by an HyQ-Tase solution (Perbio-Sciences, HyClone,
Erembodegem, BE) and were seeded on type I collagen (1% in
PBS, v:v) (Sigma-Aldrich) precoated supports. After sub-cultiva-
tion, cells were seeded at a density of 3610
4 cells per cm
2 in either
6-well plates or in 25 cm
2 flasks and grown for 9 days with
medium changes every 2 days.
Figure 1. Hypothetical metabolic pathways of conversion of t11t13 CLA into c9t11 CLA in human intestinal Caco-2 cells.
doi:10.1371/journal.pone.0032824.g001
Conversion of t11t13 CLA
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At 7 days post-confluence (9 days of culture in total), Caco-2
cells were treated with t11t13 CLA or TVA (Larodan, Malmo ¨, SE)
or with the ethanol vehicle (1%, v:v; Sigma-Aldrich) in the
presence of absence of SO (see section below) for 24 h. The fatty
acids were first dissolved in ethanol and then added to the culture
medium at a concentration of 20 mmol/l, in the presence of
1 mmol/l taurocholic acid (Sigma-Aldrich).
Preparation of sterculic oil
SO was extracted from the seeds of the Sterculia foetida tree. Seeds
were dehulled, finely ground, loosely packed into an extraction
thimble, and then placed in a Soxhlet apparatus for extraction.
Petroleum ether was refluxed through the apparatus for 8 h, and
then collected and dried using a rotary evaporator to obtain the
extracted oil. Extracted SO was then saponified basing on the
saponification protocol of Guil-Guerrero & Belarbi [38] with
adaptations in the amounts and volumes used. Briefly, about
120 mg of oil were mixed with 400 ml of a saponifying solution
made of KOH (60 mg), water (200 ml) and ethanol (200 ml; 96%,
v:v). After 1 h incubation at 70uC, 100 ml water was added and
unsaponifiables were separated by the addition of 1 ml of hexane
(Biosolve, Valkenswaard, NL). After elimination of the upper
phase (containing unsaponifiables), 240 ml of 1.2 mol/l HCL in
water were added to acidify and 1 ml of hexane was then added to
extract free fatty acids (FFA). After centrifugation, the hexane
phase containing FFA was dried under nitrogen and reconstituted
in 10 ml of ethanol. This solution of saponified oil in ethanol was
then added to the culture medium in order to reach a final
concentration of 300 mmol/l in sterculic acid, which is the most
abundant fatty acid present in SO and has been shown, with
others, to efficiently inhibit the D9D activity.
Sample preparation and separation of lipid classes by
Solid Phase Extraction
After 24 h of treatment, cells were washed, scrapped and
collected in 1 ml of PBS. The cell suspension was then divided into
two parts, one for lipid extraction and the other for protein content
determination. Both parts were pelleted by centrifugation for
10 min at 500 g.
With the first part of the sample, total cell lipids were extracted
with chloroform/methanol/water (2:2:1.8; v:v:v) (Biosolve) ac-
cording to the Bligh & Dyer method [39]. Tridecanoic acid
(C13:0; Sigma-Aldrich) was used as internal standard. Each
sample was then dried under nitrogen and methylated at 70uC
through the addition of 1 ml of 0.1 mol/l KOH in methanol and a
1 h incubation followed by the addition of 0.4 ml of 1.2 mol/l
HCL in methanol and incubation during 15 min. The fatty acid
methyl esters (FAME) were then extracted by 2 ml of hexane and
separated by GC.
Between the extraction and methylation steps, the total lipid
extracts of certain samples were separated by solid phase
extraction (Bond Elut–NH2, 200 mg, 3 ml; Varian, Middelburg,
NL) into 3 lipid fractions, i.e. neutral lipids (NL), FFA and
phospholipids (PL). A mixture of three internal standards made of
triheptadecanoin (Larodan), tridecanoic acid and 1,2-dipentade-
canoyl-sn-glycero-3-phosphatidylcholine (Larodan) was added to
each sample before lipid extraction in order to allow the
quantification of the fatty acids present in the NL, FFA and PL
fractions, respectively. After conditioning the columns with 3 ml of
hexane, the total lipid extract dissolved in 200 ml of chloroform
was loaded. After the chloroform was pulled through, the NL
fraction was eluted with 1.8 ml of chloroform/2-propanol (2:1, v:v)
(Biosolve). The column was then loaded with 2.4 ml of diethyl
ether/acetic acid (98:2, v:v) (Bioslove) followed by 1.8 ml of
methanol (Biosolve) to elute the FFA and PL fractions,
sequentially. Each fraction was then dried under nitrogen and
methylated as described above. The FAME were then extracted
by 2 ml of hexane and separated by GC.
Fatty acid analysis
The FAME obtained after extraction of cellular samples were
separated by gas chromatography as described in Dang Van et al.
[22]. Fatty acid peaks were identified using pure methyl ester
standards purchased from Larodan and from Nu-Chek Prep, Inc
(Elysian, MN).
The fatty acid composition of the oil extract (Figure 2) was also
determined by gas chromatography. Briefly, the FAME were
prepared by transesterification with sodium methoxide according
to the method of Christie [40]. They were then analysed using a
gas chromatograph (Varian Star 3400, Santa Clara, CA) equipped
with a SP2560 column (100 m60.25 mm internal diameter,
0.2 mm film thickness; Supelco, Bellefonte, PA). Gas chromato-
graph conditions were a flow rate of He of 1 ml/min with an
initial temperature of 140uC held for 5 min. The column
temperature was then increased to 250uC at a rate of 2uC.min
21,
and then held at 250uC for 15 min. Fatty acid peaks were
identified using pure methyl ester standards (Supelco).
Protein determination
The samples prepared for the determination of cell protein
contents (see above) were lysed in Reporter Lysis Buffer (RLB;
Promega, Madison, WI). Protein concentration was then deter-
mined using the Bicinchoninic Acid Protein Assay kit (Sigma-
Aldrich), which is based on the alkaline reduction of Cu
2+ to Cu
1+
by proteins followed by the formation of a purple complex of Cu
1+
with bicinchoninic acid (BCA). 25 ml of cell lysate were mixed with
200 ml BCA working reagent. After incubation at 37uC for
30 min, the Cu
1+-BCA complex formed was quantified at 600 nm
with a spectrophotometer (SpectraCount
TM, Packard, Warren-
ville, IL). Protein concentrations were calculated using a bovine
serum albumin (BSA; Sigma-Aldrich) calibration curve obtained
for each assay with a known concentration range of BSA (0.2–
2 mg/ml).
Statistics
Data for intracellular fatty acid composition are reported as
means from 3 independent experiments, each performed in
triplicates. Data were subjected to an analysis of variance
(ANOVA 1) using SAS (version 9.2; SAS Institute Inc., Cary,
NC) coupled with the Tukey test in order to identify means with
significant differences (P value ,0.05).
Results
Accumulation and conversion of t11t13 CLA
We first observed that, when 7-days post confluent Caco-2 cells
cultivated in serum-free medium were incubated during 24 h in
the presence of 20 mmol/l of t11t13 CLA, they were able to absorb
and accumulate this isomer of CLA (Table 1). Furthermore, these
cells also converted t11t13 CLA into c9t11t13 CLnA and c9t11
CLA, these fatty acids being absent from control cells.
In order to modulate the bioconversion of t11t13 CLA, we also
incubated the Caco-2 cells during 24 h, concurrently with t11t13
CLA and with SO, well known to contain inhibitors of the D9D.
We first verified that SO had no cytotoxic effects on the cells at this
concentration (results not shown). The inhibitory effect of SO in
Conversion of t11t13 CLA
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32824Figure 2. Representative gas chromatogram of sterculic oil extracted from the seeds of the Sterculia Foetidia tree. FAME were
analysed using a gas chromatograph equipped with a SP2560 column (100 m60.25 mm internal diameter, 0.2 mm film thickness). Gas
chromatograph conditions were a flow rate of He of 1 ml/min with an initial temperature of 140uC held for 5 min. The column temperature was then
increased to 250uC at a rate of 2uC.min-1, and then held at 250uC for 15 min.
doi:10.1371/journal.pone.0032824.g002
Table 1. Total fatty acid composition of Caco-2 cells.
Control Control+SO t11t13 CLA
2 t11t13 CLA+SO TVA
3 TVA+SO
Fatty acids
Mean
(ng/mg) SD
4
Mean
(ng/mg) SD
Mean
(ng/mg) SD
Mean
(ng/mg) SD
Mean
(ng/mg) SD
Mean
(ng/mg) SD
C14:0 12.8
d 1.2 17.1
a 1.1 14.2
c,d 1.6 16.7
a,b 1.5 14.9
b,c 1.1 17.1
a 1.6
C16:0 65.2
b 7.4 89.7
a 9.8 69.6
b 11.7 90.1
a 10.8 75.8
b 8.2 91.2
a 9.4
C18:0 24.9
b 3.4 40.7
a 4.8 29.2
b 3.6 41.6
a 6.0 28.7
b 3.8 42.2
a 4.9
C16:1 n-7 48.9
a 5.6 48.6
a 5.6 46.8
a 7.5 48.9
a 5.9 54.7
a 7.0 48.2
a 5.8
C18:1 n-9 94.1
a 11.2 97.4
a 7.5 94.9
a 7.6 99.1
a 10.0 107.0
a 8.8 99.0
a 9.1
C18:1 n-7 44.9
a 4.5 47.4
a 4.2 49.9
a 5.2 46.5
a 4.1 50.0
a 3.5 47.2
a 3.3
C18:2 n-6 0.1
a 0.1 0.2
a 0.1 0.1
a 0.0 0.1
a 0.1 0.1
a 0.2 0.2
a 0.3
C18:1 t11 ND
5,c ND
c ND
c ND
c 3.4
b 0.7 5.5
a 1.2
C18:2 c9t11 ND
d ND
d 1.9
a 0.4 1.4
b 0.3 2.7
a 0.6 0.9
c 0.1
C18:2 t11t13 ND
c ND
c 9.4
b 1.6 15.5
a 1.2 ND
c ND
c
C18:3 c9t11t13 ND
c ND
c 1.3
a 0.3 0.7
b 0.2 ND
c ND
c
Caco-2 cells were cultivated in serum-free medium during 7 days post-confluence and then incubated for 24 h in the presence of TVA or t11t13 CLA at 20 mmol/l in
absence or presence of sterculic oil (SO; 300 mmol/l of sterculic acid
1).
1Final concentration in culture medium.
2t11t13 CLA: t11t13 conjugated linoleic acid (C18:2 t11t13).
3TVA: trans-vaccenic acid (C18:1 t11).
4ND: not detected.
Values are means 6 SD from 3 independent experiments, each performed in triplicate (N=3, n=3) and are expressed in ng of each fatty acid per mg of cell protein.
Means in the same row without a common superscript letter differ (P,0.05).
doi:10.1371/journal.pone.0032824.t001
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of the Caco-2 cells with TVA, which can be efficiently converted
into c9t11 CLA by the D9D (Table 1). The extent of D9D activity
was evaluated from the ratio between the cellular concentration of
c9t11 CLA and the sum of TVA and c9t11 CLA concentrations.
In the absence of SO, this ratio approximated 0.44, whereas it was
limited to about 0.14 upon cultivation with SO. This lower
conversion rate of TVA in the presence of SO was associated with
a significantly higher cellular level in TVA and a significantly
lower level in c9t11 CLA. When the cells were incubated in the
presence of t11t13 CLA and SO, the cellular concentration of
t11t13 CLA was significantly increased while the abundance of
c9t11 CLA and c9t11t13 CLnA was significantly decreased. These
data implicate D9D in the first step of the conversion pathway
between t11t13 CLA and c9t11 CLA. Accordingly, no TVA could
be detected in the cells incubated with t11t13 CLA, in the absence
or even in the presence of SO.
Effect of sterculic oil on saturated and monounsaturated
fatty acids
Table 1 shows an increase in the level of saturated fatty acids
(SFA) (myristic acid, C14:0; palmitic acid, C16:0 and stearic acid,
C18:0) in all the conditions with SO. The increase in palmitic acid
may be explained, at least partially, by its relatively high
abundance in SO. Accordingly, the increase in stearic acid may
be due to an elongation of the excess of palmitic acid. By contrast,
the increase in myristic acid, which appears more limited, is likely
to be a consequence of D9D inhibition by SO. In contrast, the
cellular levels of monounsaturated fatty acids (MUFA) (palmitoleic
acid, C16:1 n-7; oleic acid, C18:1 n-9 and cis-vaccenic acid, C18:1
n-7) were not increased in the presence of SO, suggesting again an
inhibitory effect of SO. Finally, the level of linoleic acid (C18:2 n-
6) did not change when fatty acids or SO were added. In control
cells, no other fatty acid was detected. Indeed, when cultivated in a
serum-free medium, only the fatty acids that cells can synthesize de
novo were accumulated except for linoleic acid that accumulated as
a result of uptake from the nutritive medium.
Time course of accumulation and conversion of t11t13
CLA
The time course of t11t13 CLA accumulation and metabolic
processing into c9t11 CLA and c9t11t13 CLnA in Caco-2 cells
was determined by addition of t11t13 CLA at 20 mmol/l for 3 h,
6 h, 9 h, 18 h or 24 h (Figure 3). The cellular level of t11t13 CLA
increased rapidly up to 9 h (from 0 to about 7.5 ng/mg cell protein
in 9 h) and then more slowly between 9 h and 24 h (to about
10.5 ng/mg cell protein in 15 h). The cellular level of the c9t11
CLA produced from t11t13 CLA increased with the incubation
time up to 24 h. The accumulation kinetics of c9t11 CLA could be
approximated by a linear regression (R
2 of 0.995), which indicates
a constant accumulation rate throughout the one-day incubation.
Finally, the c9t11t13 CLnA intermediate also accumulated
progressively but in lower proportions. It could be detected from
9 h on and its cellular level increased up to 24 h. According to the
previous results, TVA could not be detected at any time in the cells
incubated with t11t13 CLA during this one-day incubation, in the
absence or even in the presence of SO.
Distribution into lipid classes
The distribution of the t11t13 CLA accumulated by the Caco-2
cells, as well as that of its bioconversion product, c9t11 CLA, into
the different lipid classes (NL, FFA and PL) was also determined
(Figure 4). Unfortunately, the cellular level of c9t11t13 CLnA was
too low to be detected when the cellular extract was divided in
three fractions. It was first observed that t11t13 CLA as well as its
metabolite, c9t11 CLA, were only distributed between the NL and
PL fractions, since no fatty acid could be detected in the FFA
fraction. Interestingly enough, the t11t13 CLA was found in a
Figure 3. Time course of accumulation and processing of t11t13 CLA in Caco-2 cells. Caco-2 cells were cultivated in serum-free medium
during 7 days post-confluence and then incubated with this fatty acid during 3 h, 6 h, 9 h, 18 h and 24 h at 20 mmol/l. Results are means 6 S.D from
3 independent experiments, each performed in triplicates (N=3, n=3).
doi:10.1371/journal.pone.0032824.g003
Conversion of t11t13 CLA
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accumulated more readily in the PL fraction (61%).
Discussion
Our results have shown that, upon incubation with t11t13 CLA,
Caco-2 cells are able to absorb this conjugated fatty acid, but also
to perform its metabolic processing into c9t11 CLA through the
synthesis of c9t11t13 CLnA as intermediate. This latter fatty acid
is probably produced from t11t13 CLA through the action of the
D9D. The conversion of t11t13 CLA to c9t11 CLA has already
been reported in a recent study using HT-29 cells [25]. To our
knowledge, that study was the very first to show the conversion of
one CLA isomer to another and our experiments in Caco-2 cells
confirm these data. Furthermore, the data of the present study
clarify the metabolic pathway involved in that conversion. Two
metabolic routes presented in Figure 1 were plausible candidates,
the first using TVA as intermediate and the other using c9t11t13
CLnA as intermediate. In their experiment using HT-29 cells
incubated with t11t13 CLA, Degen et al. [25] observed only the
presence of t11t13 CLA and of c9t11 CLA, and could
unfortunately not detect the presence or accumulation of one of
the two potential intermediate compounds. They were thus unable
to draw conclusions about the chronology of action of the two
enzymes required. The results of the present study definitively
show that c9t11t13 CLnA is an intermediate involved in the
conversion of t11t13 CLA to c9t11 CLA in Caco-2 cells. In
addition, the inhibition of D9D by SO decreased the cellular level
of c9t11t13 CLnA, confirming the desaturation of t11t13 CLA as
being involved in the conversion pathway. By contrast, TVA (the
other possible intermediate) was not detected, even in the presence
of SO, which would have caused an increase in its concentration.
This observation suggests the TVA route as being minor if not
absent.
Both hypothetical metabolic pathways (Figure 1) involve the
action of a D9D for the introduction of a double bond in the D9
position and of a reductase to saturate the fatty acid in the D13
position. D9D is a well-known enzyme with a broad substrate
range [41] including TVA [16–21]. Among others, TVA was
shown to be partly converted into c9t11 CLA in Caco-2 cells [42].
We confirmed these results in the present study. In addition, we
showed a potent inhibitory effect of SO on that desaturation since
a significantly higher cellular level of TVA and a significantly
lower cellular level of c9t11 CLA were found in the presence of
SO. The reductase activity targeting the D13 position is much less
documented. It is know that c9t11t13 CLnA present in tung oil or
in bitter gourd seed oil can be converted into c9t11 CLA in the
liver, kidney and small intestine of rats and mice fed with these oils
[28–31]. We have very recently shown that c9t11t13 CLnA can be
reduced to c9t11 CLA in Caco-2 cells, in the same culture
conditions as in this present study [33]. The enzyme involved in
this conversion and the mechanism of action are however still not
clearly identified. Tsuzuki et al. [28,29] showed that c9t11t13
CLnA and c9t11c13 CLnA were saturated at the D13 position by
a NADPH-dependent enzyme and converted into c9t11 CLA.
The authors speculated that this D13 saturation was carried out
either by an unknown enzyme recognizing conjugated trienoic
acids or by the enzyme active in the leukotriene B4 reductive
pathway, namely leukotriene B4 12-hydroxydehydrogenase also
named 15-ketoprostaglandin D13-reductase. Interestingly, Moise
et al. [43,44] recently described a retinol saturase, which carries out
the saturation of the D13 double bond of the all-trans-retinol to
produce all-trans-13,14-dihydroretinol. This enzyme may thus be
another candidate for the D13 reduction of c9t11t13 CLnA. The
fact that no TVA was detected in cells incubated with t11t13 CLA
and SO suggests that the D13-reductase active on the fatty acids
under investigations can not act on a fatty acid without a double
bond in the D9 position.
A broader analysis of the cellular fatty acid profiles (Table 1)
suggests that SO also influenced the synthesis of some fatty acids
constantly produced de novo by the cells, even though its presence
was limited to the last 24 h of incubation. This effect is visible for
myristic acid, which is not present in SO. Its cellular accumulation
is indeed significantly higher in the conditions with SO. For
palmitic and stearic acids, the situation is less clear since palmitic
acid may have been accumulated from SO added to the medium
and then partly converted to stearic acid.
The t11t13 CLA was efficiently absorbed by the Caco-2 cells
and this absorption was proportional to the duration of incubation
for the first 9 h, and then slowed down. By contrast, accumulation
of the conversion product c9t11 CLA, appeared to follow a linear
kinetics during the whole experimental period of 24 h. As for the
c9t11t13 CLnA intermediate, its accumulation pattern was again
different. Indeed, no c9t11t13 CLnA was detected before 9 h of
incubation and from this moment, its level increased slowly. Taken
together, these observations suggest that the kinetics of the two
enzymes involved are influenced differently in the range of
concentrations encountered in the cells in the present experiment.
The distribution of t11t13 CLA and its bioconversion product,
c9t11 CLA, into the different lipid classes (NL, FFA and PL)
accumulated by the Caco-2 cells revealed intriguing differences.
Unfortunately, the level of c9t11t13 CLnA was too low to be
detected when the cellular extract was divided into the three
fractions. The distribution of these CLA isomers was different but
in both cases they were only distributed between the NL and PL
fractions. We observed that the bulk of t11t13 CLA was found in
the NL fraction while the isomer c9t11 CLA was principally found
in the PL fraction. This difference in distribution could result from
either the number of trans double bonds (one for c9t11 CLA and
two for t11t13 CLA), the position of the double bonds (9,11 versus
11,13) or a combination of both. We have previously shown that
Figure 4. Incorporation of t11t13 CLA and its metabolite c9t11
CLA into different lipid fractions. Lipid fractions (neutral lipids (NL),
free fatty acids (FFA) and phospholipids (PL)) were prepared from Caco-
2 cells cultivated in serum-free medium during 7 days post-confluence
and then incubated with t11t13 CLA (20 mmol/l) for 24 h. Results are
means from 3 independent experiments (N=3, n=1).
doi:10.1371/journal.pone.0032824.g004
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differing only in terms of cis or trans configuration of their three
double bonds, was correlated to the number of trans double bonds
[33]. The same might be true here. Furthermore, we also showed
that the relative position of the trans double bonds in the four
CLnA bearing insaturations at the three same positions (9,11 and
13) seemed without influence on the repartition between the NL
and PL fractions. Indeed, c9t11t13 CLnA and t9t11c13 CLnA
were identically distributed between these two fractions. In that
previous study, the distribution of c9t11 CLA between NL and PL
was of 33–38% and 62–67%, respectively [33]. Similar results are
obtained in the present study (61% in PL and 39% in NL),
suggesting that the distribution of c9t11 CLA is independent from
the substrate it originates: t11t13 CLA or CLnA. In contrast to the
similarities in distribution for c9t11 CLA in the present study and
in the previous one [33], differences appear if we compare the
distribution of t11t13 CLA in the present study (38% in PL and
62% in NL) with that of t9t11 CLA in the previous study [33] (53–
55% in PL and 45–47% in NL), suggesting that, in addition to the
number of trans double bonds, their position does influence the cell
fatty acid distribution pattern between PL and NL.
In conclusion, the present results tend to confirm that human
enterocytes represented here by Caco-2 cells are able to convert
one isomer of CLA into another one. In addition, they indicate
that during the conversion of t11t13 CLA into c9t11 CLA, t11t13
CLA undergoes first a desaturation step catalysed by the D9D and
then a reduction step targeting the double bond at the D13
position. We suggest here that this second enzyme is the same as
the enzyme responsible of the conversion of CLnA into CLA.
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